Waters Corporation
WAT Healthcare Diagnostics & Research
Waters Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 6.99% from fiscal 2024. In the quarter to June 2026, revenue grew 113.4%, EPS fell 156.3%, free cash flow grew 750.0% and total debt rose 308.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow WAT
Waters Corporation (WAT) EBITDA
Waters Corporation's EBITDA for fiscal 2025 was $1.0B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $942.8M. Over the past ten years it has ranged from $657.4M (fiscal 2015) to $1.0B (fiscal 2024); the current reading is higher than 91% of that period. Waters Corporation ranks 10th of 52 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.0B | (0.92%) |
| FY2024 | $1.0B | 3.52% |
| FY2023 | $983.6M | (2.02%) |
| FY2022 | $1.0B | 5.29% |
| FY2021 | $953.4M | 23.68% |
| FY2020 | $770.9M | (5.27%) |
| FY2019 | $813.8M | (4.06%) |
| FY2018 | $848.2M | 10.41% |
| FY2017 | $768.2M | 6.47% |
| FY2016 | $721.5M | 9.74% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $215.0M | 34.38% |
| Mar 2026 | $160.0M | (50.47%) |
| Dec 2025 | $323.0M | 31.95% |
| Sep 2025 | $244.8M | 2.43% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| IQV IQVIA Holdings Inc. compare | $3.4B |
| DGX Quest Diagnostics Incorporated compare | $2.2B |
| LH Labcorp Holdings Inc. compare | $2.2B |
| A Agilent Technologies, Inc. compare | $1.9B |
| IDXX IDEXX Laboratories, Inc. compare | $1.6B |
| MTD Mettler-Toledo International, Inc. compare | $1.3B |
| ILMN Illumina, Inc. compare | $1.2B |
| WAT Waters Corporation | $942.8M |
| NTRA Natera, Inc. compare | −$223.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on WAT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement